Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Sep 29, 2026
Pershing Square (PS) Climbs +40% in 30 Days: Drivers Behind the Recent Advance

Pershing Square (PS) Climbs +40% in 30 Days: Drivers Behind the Recent Advance

Key Takeaways

  • Pershing Square (PS) shares climbed roughly 40% over the past 30 days, from about $42 to about $59 per share.
  • The move was fueled by enthusiasm around a new permanent-capital vehicle, Pershing Square Ventures, plus a broader crypto-linked market rally.
  • Over roughly the last quarter, the stock has risen approximately 78%, building on its April 2026 NYSE debut.
  • Firmwide assets under management reached about $33 billion as of August 31, 2026, supporting the company's fee-based growth story.
  • Analysts currently hold a consensus "Hold" rating with an average price target near $42, well below the recent trading price.

Company Background and Market Position

Pershing Square Inc. is a New York–based alternative asset manager led by Bill Ackman and serves as the parent company of Pershing Square Capital Management, an SEC-registered investment adviser. The firm manages concentrated, research-driven portfolios focused primarily on large-capitalization North American equities. The company began trading on the New York Stock Exchange on April 29, 2026, following a combined initial public offering alongside its U.S. closed-end vehicle, Pershing Square USA (PSUS), which together raised $5 billion. Investors follow Pershing Square (PS) closely because its business model is built on durable, fee-paying permanent capital and because its growth is closely tied to the performance of Ackman's investment decisions. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stock Price Performance Over the Last 30 Days and Quarter

Over the last 30 days, PS shares advanced from roughly $42 to about $59, a gain of approximately 40%. The rally was not linear: the stock pulled back from the low $42s into the mid-$36 range in early September before a sharp reacceleration in the second half of the month. On a quarterly basis, the move is even more pronounced. From about $33 at the start of July, the stock has risen roughly 78%, reflecting a sustained upward trend that has been punctuated by periods of volatility and a notable jump in trading volume during the final weeks of the period.

Factors Behind the 30-Day Price Move

The primary catalyst was the firm's push into new permanent-capital growth. In August, Pershing Square drew $30 million from its revolving credit facility to seed Pershing Square Ventures, a planned fund focused on late-stage private companies. Management has signaled a target launch around fall to year-end, and investors have repriced the stock on the prospect of an additional fee-generating platform layered on top of the firm's existing permanent capital. Broader market dynamics also played a role. During the week ending September 18, PS was a standout performer in the financial sector as Bitcoin rallied toward $81,000 and investors rotated into crypto-adjacent and alternative-asset names. The stock gained more than 32% in that week alone. Ackman's commentary on the earnings call highlighting the potential value of the firm's large Fannie Mae (FNMA) and Freddie Mac (FMCC) holdings also reinforced the idea that a favorable policy outcome could materially lift fee-paying assets. From what I see, this combination of company-specific news and sector tailwinds explains much of the recent strength.

Drivers of Quarterly Performance

The quarterly advance reflects a broader narrative of transition and expansion. Since its April debut, Pershing Square has emphasized its "permanent capital" model, noting that roughly 98% of its capital is permanent in nature. Second-quarter results showed management fees of $54.18 million, and the firm reported about $33 billion in firmwide assets under management as of August 31. The launch of Pershing Square Ventures extended that story, giving investors a concrete path toward additional management-fee revenue beyond the core public-equities platform. On the analyst side, Tigress Financial raised its price target to $41 from $39 in early September, citing the expanding permanent capital base and the firm's high-margin earnings model. The combination of a growing AUM base, new fund ambitions, and favorable market sentiment underpinned the stock's multi-month advance.

Key Areas to Monitor Going Forward

Investors should monitor several factors ahead. The formal launch and fundraising progress of Pershing Square Ventures will be a key test of whether the new platform can meaningfully add to fee-paying assets. Underlying portfolio performance remains central, since appreciation in the firm's concentrated holdings directly drives management fees. Policy developments around the government-sponsored enterprises, including any action on Fannie Mae and Freddie Mac, could represent a significant catalyst given the size of the firm's positions. Quarterly earnings, updates to assets under management, and any shifts in analyst ratings or price targets will also shape sentiment. Finally, broader market conditions, including crypto-market momentum and sector rotation within financials, may continue to influence near-term price action. As with any concentrated, performance-driven asset manager, execution risk and the dependence on investment returns remain important considerations. I’m watching this closely as the story unfolds.

Exploring AI-Powered Trading Insights

In my analysis of names like PS, I often turn to Tickeron’s AI tools to cross-check patterns and performance metrics. One resource that stands out is the Trending AI Robots page, which curates a view of actively trading AI-powered bots across thousands of tickers. It highlights only the top-performing and most relevant strategies, allowing users to explore options that fit different timeframes and risk profiles. This can serve as a helpful supplement when evaluating how broader market signals align with individual stock movements.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for PS turns positive, indicating new upward trend

PS saw its Momentum Indicator move above the 0 level on September 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 4 similar instances where the indicator turned positive. In 4 of the 4 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for PS just turned positive on September 17, 2026. Looking at past instances where PS's MACD turned positive, the stock continued to rise in 2 of 2 cases over the following month. The odds of a continued upward trend are 90%.

PS moved above its 50-day moving average on September 11, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +13.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where PS advanced for three days, in 14 of 16 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

The Aroon Indicator entered an Uptrend today. In 4 of 4 cases where PS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The 10-day RSI Indicator for PS moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 4 similar instances where the indicator moved out of overbought territory. In 4 of the 4 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 3 of 3 cases where PS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

PS broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PS's P/B Ratio (17.391) is very high in comparison to the industry average of (3.242). P/E Ratio (0.000) is within average values for comparable stocks, (26.802). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.341). PS has a moderately low Dividend Yield (0.002) as compared to the industry average of (0.081). P/S Ratio (21.692) is also within normal values, averaging (15.853).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Notable companies

The most notable companies in this group are Ares Capital Corp (NASDAQ:ARCC), WisdomTree (NYSE:WT), AMTD IDEA Group (NYSE:AMTD).

Industry description

Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.

Market Cap

The average market capitalization across the Investment Managers Industry is 8.63B. The market cap for tickers in the group ranges from 57 to 165.9B. BLK holds the highest valuation in this group at 165.9B. The lowest valued company is RSERF at 57.

High and low price notable news

The average weekly price growth across all stocks in the Investment Managers Industry was -1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 9%. SDEV experienced the highest price growth at 151%, while INV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Investment Managers Industry was 35%. For the same stocks of the Industry, the average monthly volume growth was 93% and the average quarterly volume growth was 18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 30
P/E Growth Rating: 53
Price Growth Rating: 55
SMR Rating: 67
Profit Risk Rating: 81
Seasonality Score: 38 (-100 ... +100)
View a ticker or compare two or three
PS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an online technology learnings platform

Industry InvestmentManagers

Industry
Information Technology Services
Address
787 Eleventh Avenue
Phone
+1 212 813-3700
Employees
44
Web
N/A
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.